LeadScope Inc (AKA: Columbus Molecular Software) Profile last edited on: 12/20/2019
CAGE: 3XND5
UEI: PDMWJQKHBWG7
Business Identifier: Cheminformatic tools for drug lead identification and optimization 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 15
County: Franklin
Congr. District: 15
County: Franklin
Public Profile
Formerly doing business as Columbus Molecular Software, Inc., LeadScope, Inc. develops and markets a chemofinformatics application that provides access to research data. The firm offers toxicity databases, data management and decision support solutions, and Leadscope databases. Also provided are In silico tox, data mining, HTS analysis, lead optimization, and compound acquisition solutions. Leadscope serves national labs; pharmaceutical, biotechnology, chemical, and consumer products companies; and regulatory agencies in the United States, Canada, and Europe. In November 2019 it was announced that Leadscope, Inc. had been acquired by Pennsylvania-based, publicly traded Instem (LSE:INS) providing advanced IT solutions to global health and life sciences community to improve productivity of discovery and development of new drugs, therapies and products.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
10-14Revenue Range
1M-1.5MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
1-4Awards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2019 | 2 | NIH | $1,149,071 | |
| Project Title: Rapid response toxicology prediction platform | ||||
| 2014 | 1 | NIH | $149,182 | |
| Project Title: Computational Platform for Green Chemistry | ||||
| 2010 | 1 | NIH | $150,000 | |
| Project Title: Tas::75 0862::Tas Sbir Phase I; Topic 108r&D-Other R & D-B Res | ||||
| 2003 | 2 | NIH | $200,000 | |
| Project Title: A Novel Chemical Genomics Methodology | ||||
Key People / Management
Loftus Lucas -- CEO
Michael Conley -- Chief Financial Officer,
Kevin Cross -- Vice President of Product Engineering
Glenn John Myatt -- Chief Scientific Officer, Co-Founder,
Chihae Yang
Michael Conley -- Chief Financial Officer,
Kevin Cross -- Vice President of Product Engineering
Glenn John Myatt -- Chief Scientific Officer, Co-Founder,
Chihae Yang
